Kodiak Sciences Q3 2026 Results: Net Loss of $66.2M, Loss Widens
Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.
- Key figure
- Net loss $66.2M